We are live on ! Find out more
AA

Antipodean Advisors Portfolio holdings

AUM $19.5M
1-Year Est. Return 6.21%
This Fund
S&P 500
This Quarter Est. Return
+1.29%
1 Year Est. Return
-6.21%
3 Year Est. Return
-67.79%
5 Year Est. Return
+67.26%
10 Year Est. Return
+1,117.22%
AUM
$353M
AUM Growth
-$9.95M
Cap. Flow
+$7.46M
Cap. Flow %
2.11%
Top 10 Hldgs %
100%
Holding
11
New
3
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
IBN icon
ICICI Bank
IBN
+$7.5M
2
IVVD icon
Invivyd
IVVD
+$7.05M
3
NKLA
Nikola Corporation Common Stock
NKLA
+$1.17M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$717K

Top Sells

Rank Stock Value
1
CLVT icon
Clarivate
CLVT
+$3.65M
2
CLOV icon
Clover Health Investments
CLOV
+$3.13M
3
LMND icon
Lemonade
LMND
+$2.19M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 66.47%
2 Communication Services 15.18%
3 Healthcare 9.24%
4 Technology 6.98%
5 Financials 2.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVNA icon
1
Carvana
CVNA
$47.5B
$122M 34.58%
2,025,000
– –
SE icon
2
Sea Limited
SE
$66.4B
$112M 31.59%
350,000
– –
CDLX icon
3
Cardlytics
CDLX
$22.2M
$53.6M 15.18%
63,880
– –
CLVT icon
4
Clarivate
CLVT
$1.37B
$24.6M 6.98%
1,125,000
-150,000
-12% -$3.65M
ATRA icon
5
Atara Biotherapeutics
ATRA
$72.6M
$18.8M 5.32%
42,000
+2,000
+5% +$717K
IVVD icon
6
Invivyd
IVVD
$160M
$8.03M 2.27%
+190,000
New +$7.05M
IBN icon
7
ICICI Bank
IBN
$107B
$7.55M 2.14%
+400,000
New +$7.5M
CMAX
8
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$5.8M 1.64%
20,000
– –
NKLA
9
DELISTED
Nikola Corporation Common Stock
NKLA
$1.07M 0.3%
+3,333
New +$1.17M
CLOV icon
10
Clover Health Investments
CLOV
$2.23B
– –
-235,000
Closed -$3.13M
LMND icon
11
Lemonade
LMND
$3.64B
– –
-20,000
Closed -$2.19M

Similar funds

CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CCFM
Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return

Antipodean Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Antipodean Advisors held 11 positions worth $353M, down 2.7% from $363M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Antipodean Advisors's Q3 2021 filing shows 3 new, 1 increased, 1 reduced and 2 closed positions. Its largest new stake was ICICI Bank: 400,000 shares worth $7.55M. The largest sale was Clarivate, an estimated $3.65M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 66% of assets, up from 60% a quarter earlier, followed by Communication Services and Healthcare.

  • Antipodean Advisors's largest Q3 2021 buy was ICICI Bank: 400,000 shares worth $7.55M.
  • Antipodean Advisors added most to Atara Biotherapeutics in Q3 2021, an estimated $717K increase.
  • Antipodean Advisors's biggest Q3 2021 reduction was Clarivate, cutting an estimated $3.65M.
  • Antipodean Advisors fully exited Clover Health Investments in Q3 2021, selling an estimated $3.13M.
  • Antipodean Advisors's ten largest holdings make up 100% of its $353M portfolio in Q3 2021.
  • Antipodean Advisors opened 3 new positions and closed 2 in Q3 2021.
  • Antipodean Advisors's portfolio value fell 2.7% quarter-over-quarter to $353M.

Based on Antipodean Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.